FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to molecular biology. There are presented peptides being GLP-1 derivatives, binding to GLP-1 receptors and used either marked, or unmarked for preparing a product for diagnosing and treating benign and malignant diseases, wherein GLP-1 receptor expression is of importance.
EFFECT: preparing the product for diagnosing and treating the benign and malignant diseases, wherein GLP-1 receptor expression is of importance.
23 cl, 4 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| INVENTION RELATING TO GLP-1 AND EXENDINS | 2005 |
|
RU2489443C2 |
| PEPTIDE EXENDIN-4 DERIVATIVES | 2005 |
|
RU2420536C2 |
| FUSED DRUG CONSTRUCTS AND CONJUGATES | 2005 |
|
RU2428431C2 |
| RADIOACTIVE METAL-LABELLED ANTI-CADHERIN ANTIBODY | 2011 |
|
RU2577125C2 |
| DUAL GLP1/GIP OR TRIGONAL GLP1/GIP/GLUCAGON AGONISTS | 2013 |
|
RU2652783C2 |
| PHARMACEUTICAL COMPOSITION FOR NON-ALCOHOLIC FATTY LIVER DISEASE PREVENTION OR TREATMENT | 2013 |
|
RU2635966C2 |
| DERIVATIVE OF INSULINOTROPIC PEPTIDE THAT CONTAINS MODIFIED N-ENDED AMINOACID | 2008 |
|
RU2442792C2 |
| BOMBESIN ANALOGUE PEPTIDE ANTAGONIST CONJUGATES | 2009 |
|
RU2523531C2 |
| SOMATOSTATINE PEPTIDES | 1996 |
|
RU2160741C2 |
| INSULINOTROPIC PEPTIDE DERIVATIVE WITH MODIFIED N-TERMINAL CHARGE | 2014 |
|
RU2673179C2 |
